{"componentChunkName":"component---src-templates-study-details-page-js","path":"/en/study/207832","result":{"data":{"studyNotFoundJson":{"title":"Study not found","content":{"childMarkdownRemark":{"html":"<p>If you entered a web address please check it was correct.</p>\n<p>You can also try <a href=\"/en/studies\">Search Page</a> to find the study you are looking for.</p>"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"<p>A unique number for a study given by ViiV.</p>"}},"ctGov":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.</p>"}},"eudraCT":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.</p>"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"false","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"false","masked_investigator":"false","masked_subject":"false","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"","acronym":"","allocation":"","arm_groups":[{"arm_group_label":"ART experienced HIV positive subjects","arm_group_description":"HIV positive subjects who have initiated any INSTI or DRV between 01 August 2013 and 31 December 2016 will be included in the study sample. The subjects will be identified from OPERA database.","arm_type":""},{"arm_group_label":"ART naive HIV positive subjects","arm_group_description":"HIV positive subjects initiating any INSTI or DRV for the first time between 01 August 2013 and 31 December 2016 will be included in the study sample. The subjects will be identified from OPERA database.","arm_type":""}],"assignment":"","brief_summary":"Integrase strand transfer inhibitors (INSTI) such as DTG are the newest tool for prolonging survival and improving quality of life for HIV positive subjects. This study will assess the overall safety profile of INSTI such as DTG, which in turn will provide additional information for clinicians while designing treatment strategies. This is an observational study, which will utilize the electronic medical record (EMR) data obtained from the Observational Pharmaco-Epidemiology Research & Analysis (OPERA®) database. The observation period of subjects initiating any INSTI or darunavir (DRV) will begin on 01 August 2013 and proceed until 31 December 2017. OPERA is a registered trademark of Epividian, Healthcare Analytics and Software firm.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"A Comprehensive Assessment of Adverse Events and Overall Safety Profile in HIV Positive Patients Treated with Dolutegravir as Compared to Other Integrase Strand Transfer Inhibitors or Darunavir","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"Infection, Human Immunodeficiency Virus","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 21:26:15","criteria":"Inclusion Criteria: - A diagnosis of HIV-1, a positive HIV-1 Western Blot, or a positive HIV-1 enzyme-linked immunosorbent assay (ELISA); and a detectable HIV-1 viral load test. - At least 13 years of age at the index date. - ART naïve or experienced. - Initiation of DTG or elvitegravir (EVG) or raltegravir (RAL) or DRV between August 01, 2013 and December 31, 2016. Exclusion Criteria: - HIV negative - A diagnosis of HIV-2, a positive HIV-1/HIV-2 Multi-spot, a positive HIV-2-specific ELISA, a positive HIV-2 Western Blot or a detectable HIV-2 viral load test. - Subjects prescribed monotherapy regimens (includes 1 core agent with or without a pharmacokinetic [PK] boosting agent). - Subjects prescribed post-exposure prophylaxis (PEP) or pre-exposure prophylaxis (PrEP).","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 4","display_phase_internal":"PHASE_4","display_status":"Planned","display_status_internal":"RECSTATUS_O_PLANNED","endpoint":"","enrollment":"1","exclusion":"","gender":"Both","gender_based":"","gender_description":"","healthy_volunteers":"None","id":"250054bb-abae-50b0-8a15-c61eafaff62b","internal":{"content":null,"contentDigest":"24f5702562725ceceaa2b4883a05bf4e","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria: - A diagnosis of HIV-1, a positive HIV-1 Western Blot, or a positive HIV-1 enzyme-linked immunosorbent assay (ELISA); and a detectable HIV-1 viral load test. - At least 13 years of age at the index date. - ART naïve or experienced. - Initiation of DTG or elvitegravir (EVG) or raltegravir (RAL) or DRV between August 01, 2013 and December 31, 2016. Exclusion Criteria: - HIV negative - A diagnosis of HIV-2, a positive HIV-1/HIV-2 Multi-spot, a positive HIV-2-specific ELISA, a positive HIV-2 Western Blot or a detectable HIV-2 viral load test. - Subjects prescribed monotherapy regimens (includes 1 core agent with or without a pharmacokinetic [PK] boosting agent). - Subjects prescribed post-exposure prophylaxis (PEP) or pre-exposure prophylaxis (PrEP).","interventions":[{"arm_group_label":"ART experienced HIV positive subjects","intervention_description":"DRV is a protease inhibitor used to treat HIV infection.","intervention_name":"DRV","intervention_type":"drug"},{"arm_group_label":"ART naive HIV positive subjects","intervention_description":"DRV is a protease inhibitor used to treat HIV infection.","intervention_name":"DRV","intervention_type":"drug"},{"arm_group_label":"ART experienced HIV positive subjects","intervention_description":"RAL is an integrase strand transfer inhibitor used to treat HIV infection.","intervention_name":"RAL","intervention_type":"drug"},{"arm_group_label":"ART naive HIV positive subjects","intervention_description":"RAL is an integrase strand transfer inhibitor used to treat HIV infection.","intervention_name":"RAL","intervention_type":"drug"},{"arm_group_label":"ART experienced HIV positive subjects","intervention_description":"DTG is an integrase strand transfer inhibitor used to treat HIV infection.","intervention_name":"DTG","intervention_type":"drug"},{"arm_group_label":"ART naive HIV positive subjects","intervention_description":"DTG is an integrase strand transfer inhibitor used to treat HIV infection.","intervention_name":"DTG","intervention_type":"drug"},{"arm_group_label":"ART experienced HIV positive subjects","intervention_description":"EVG is an integrase strand transfer inhibitor used to treat HIV infection.","intervention_name":"EVG","intervention_type":"drug"},{"arm_group_label":"ART naive HIV positive subjects","intervention_description":"EVG is an integrase strand transfer inhibitor used to treat HIV infection.","intervention_name":"EVG","intervention_type":"drug"}],"interventional_subtype":"","is_fda_regulated":false,"is_high_value":false,"is_ind_study":false,"keywords":["Integrase Strand Transfer Inhibitors","Dolutegravir","OPERA","Human Immunodeficiency Virus","Safety","Darunavir"],"last_follow_up_date":"06/29/2018 00:00:00","links":[],"locations":[],"masking":"","maximum_age_raw":"","maximum_age":null,"minimum_age":"13Years","minimum_age_raw":"13Years","modified_date":"10/01/2018 22:46:53","number_of_arms":"0","observational_design":{"biospecimen_description":"","biospecimen_retention":"None retained","number_of_groups":"0","observational_study_design":"Cohort","patient_registry":"false","target_duration_quantity":"","target_duration_units":"","timing":"Retrospective"},"official_title":"A Comprehensive Assessment of Adverse Events and Overall Safety Profile in HIV Positive Patients Treated with Dolutegravir as Compared to Other Integrase Strand Transfer Inhibitors or Darunavir","org_study_id":"207832","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Not yet recruiting - Observational","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"Phase 4","primary_compl_date":"06/29/2018 00:00:00","primary_outcomes":[{"outcome_description":"","outcome_measure":"Age of subjects","outcome_time_frame":"Within 12 months prior to index date","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Race/Ethnicity of subjects","outcome_time_frame":"Within 12 months prior to index date","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Number of subjects with history of syphilis","outcome_time_frame":"Within 12 months prior to index date","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Marital status of subjects","outcome_time_frame":"Within 12 months prior to index date","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Number of subjects belonging to a particular geographic region","outcome_time_frame":"Within 12 months prior to index date","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Number of subjects with Payer type","outcome_time_frame":"Within 12 months prior to index date","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"HIV viral load at initiation of each INSTI or DRV","outcome_time_frame":"Within 12 months prior to index date","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Cluster of differentiation (CD) 4 cell count at initiation of each INSTI or DRV","outcome_time_frame":"Within 12 months prior to index date","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Number of subjects who are antiretroviral therapy (ART) naïve at index date","outcome_time_frame":"Up to 3.4 years","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Number of ART experienced subjects with classes of ART","outcome_time_frame":"Within 12 months prior to index date","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Duration of INSTI exposure","outcome_time_frame":"Within 12 months prior to index date","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Number of subjects with year of ART initiation","outcome_time_frame":"Within 12 months prior to index date","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Number of subjects with year of regimen of interest initiation","outcome_time_frame":"Within 12 months prior to index date","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Duration of previous regimen","outcome_time_frame":"Within 12 months prior to index date","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Time from first active date to index date","outcome_time_frame":"Up to 3.4 years","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Time between index and end of follow-up","outcome_time_frame":"Up to 4.4 years","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Number of pregnant subjects at index date","outcome_time_frame":"Up to 3.4 years","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Number of subjects with AIDS defining illnesses at index date","outcome_time_frame":"Up to 3.4 years","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Number of subjects at mortality risk","outcome_time_frame":"Within 12 months prior to index date","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Number of subjects with comorbid conditions","outcome_time_frame":"Up to 3.4 years","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Number of concomitant medications used by subjects","outcome_time_frame":"Within 12 months prior to index date","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Number of subjects with pre-existing adverse events","outcome_time_frame":"Up to 4.4 years","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Number of subjects with incident adverse events","outcome_time_frame":"Up to 4.4 years","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Frequency of drug discontinuation","outcome_time_frame":"Up to 4.4 years","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Time to drug discontinuation","outcome_time_frame":"Up to 4.4 years","outcome_safety_issue":null}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":null,"outcome_measure":null,"outcome_time_frame":null,"outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["N/A"]},"start_date":"01/12/2018 00:00:00","study_type":"Observational","therapeutic_area":"","citations":[],"is_section_801":null}},"pageContext":{"studyId":"207832"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}